BioNTech Secures 1.34 Billion Investment: Revolutionizing Immunotherapy for a Healthier Future

BioNTech SE is excited to announce that the company has raised EUR 1,340,000,000 in a landmark funding round, a testament to the trust and support from investors who share our vision of transforming groundbreaking science into life-saving therapies. As a global biotechnology leader headquartered in Mainz, Germany, BioNTech has dedicated itself to harnessing the power of the immune system to fight cancer and infectious diseases by advancing innovative immunotherapies and mRNA technologies. With a workforce of nearly 7,000 pioneers spread across the world, our company is continuously driven by the mission of improving health outcomes for people everywhere. Since our founding in 2008 by a group of visionary scientists and physicians, we have been at the forefront of research that merges fundamental science with clinical excellence, focusing especially on individualized cancer medicine and tailored immunotherapies. The substantial funds raised in this round will be strategically deployed to accelerate our R&D initiatives, expand our production capabilities, and foster collaborations with leading research institutions globally. This investment will also help scale our operations as we explore new avenues for mRNA-based vaccines, a field in which some of our co-founders bring over 25 years of pioneering experience. Our commitment to scientific rigor and passion not only drives us to push the boundaries of biotechnology but also inspires us to translate innovative ideas into tangible, real-world therapeutic solutions. We are immensely proud of this milestone and invite you to join us on our journey to make a lasting impact on global health—discover career opportunities and learn more about our mission at www.biontech.com/careers.